Myc Proto Oncogene Protein Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, and Companies by DelveInsight | Biogenera SpA, Ceptur Therapeutics Inc, Cothera Bioscience, more

As per DelveInsight's assessment, globally, Myc Proto Oncogene Protein pipeline constitutes 12+ key companies continuously working towards developing 12+ Myc Proto Oncogene Protein treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
(Albany, USA) "Myc Proto Oncogene Protein Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Myc Proto Oncogene Protein Market.

The Myc Proto Oncogene Protein Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for free Sample Report @ Myc Proto Oncogene Protein Pipeline Insight [https://www.delveinsight.com/sample-request/myc-proto-oncogene-protein-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key takeaways from the Myc Proto Oncogene Protein Pipeline Report:

*
Myc Proto Oncogene Protein Companies across the globe are diligently working toward developing novel Myc Proto Oncogene Protein treatment therapies with a considerable amount of success over the years.

*
Myc Proto Oncogene Protein companies working in the treatment market are Linnane Pharma, Peptomyc, Moleculin Biotech, Cothera Bioscience, EpicentRx, and others, are developing therapies for the Myc Proto Oncogene Protein treatment

*
Emerging Myc Proto Oncogene Protein therapies in the different phases of clinical trials are- MYC degrader, OMO- 103, WP-1066, PC 002, RRx-001, and others are expected to have a significant impact on the Myc Proto Oncogene Protein market in the coming years.

*
In August 2022, EpicentRx has launched a trial named "REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study" to investigate the sequential administration of RRx-001 with a platinum doublet compared to a platinum doublet alone in treating Small Cell Lung Cancer patients in their third line of treatment or later. This global Phase 3 study aims to determine the potential superiority of RRx-001 combined with platinum chemotherapy over platinum chemotherapy alone for advanced-stage small cell lung cancer.

Myc Proto Oncogene Protein Overview

The Myc proto-oncogene protein, often referred to simply as c-Myc, is a transcription factor encoded by the MYC gene in humans. It plays a crucial role in regulating the expression of numerous genes involved in cell growth, proliferation, differentiation, and apoptosis (programmed cell death). Dysregulation or overexpression of c-Myc is commonly associated with various cancers, where it contributes to tumor initiation, progression, and metastasis.

Get a Free Sample PDF Report to know more about Myc Proto Oncogene Protein Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/myc-proto-oncogene-protein-pipeline-insights [https://www.delveinsight.com/report-store/myc-proto-oncogene-protein-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Emerging Myc Proto Oncogene Protein Drugs Under Different Phases of Clinical Development Include:

*
MYC degrader: Linnane Pharma

*
OMO- 103: Peptomyc

*
WP-1066: Moleculin Biotech

*
PC 002: Cothera Bioscience

*
RRx-001: EpicentRx

Route of Administration

Myc Proto Oncogene Protein pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

*
Oligonucleotide

*
Peptide

*
Small molecule

Myc Proto Oncogene Protein Pipeline Therapeutics Assessment

*
Myc Proto Oncogene Protein Assessment by Product Type

*
Myc Proto Oncogene Protein By Stage and Product Type

*
Myc Proto Oncogene Protein Assessment by Route of Administration

*
Myc Proto Oncogene Protein By Stage and Route of Administration

*
Myc Proto Oncogene Protein Assessment by Molecule Type

*
Myc Proto Oncogene Protein by Stage and Molecule Type

DelveInsight's Myc Proto Oncogene Protein Report covers around products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Myc Proto Oncogene Protein product details are provided in the report. Download the Myc Proto Oncogene Protein pipeline report to learn more about the emerging Myc Proto Oncogene Protein therapies [https://www.delveinsight.com/sample-request/myc-proto-oncogene-protein-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key companies in the Myc Proto Oncogene Protein Therapeutics Market include:

Key companies developing therapies for Myc Proto Oncogene Protein are - Biogenera SpA, Ceptur Therapeutics Inc, Cothera Bioscience Pty Ltd, Erasca Inc, Phylogica Limited, Dicerna Pharmaceuticals, Inc., Sorrento Therapeutics, Inc, Anima Biotech Inc, Arrakis Therapeutics Inc, Arvinas Inc, Escend Pharmaceuticals Inc, Gibson Oncology LLC, and Kintor Pharmaceutical, and others.

Myc Proto Oncogene Protein Pipeline Analysis:

The Myc Proto Oncogene Protein pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Myc Proto Oncogene Protein with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myc Proto Oncogene Protein Treatment.

*
Myc Proto Oncogene Protein key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Myc Proto Oncogene Protein Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myc Proto Oncogene Protein market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Myc Proto Oncogene Protein drugs and therapies [https://www.delveinsight.com/sample-request/myc-proto-oncogene-protein-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Myc Proto Oncogene Protein Pipeline Market Drivers

*
Technological advancements toward cMyc-Max Inhibition, growing interest of Pharma and research community to develop different strategies to target cMycproteins are some of the important factors that are fueling the Myc Proto Oncogene Protein Market.

Myc Proto Oncogene Protein Pipeline Market Barriers

*
However, undesirable side effects on normal cells, lack of approved therapies and other factors are creating obstacles in the Myc Proto Oncogene Protein Market growth.

Scope of Myc Proto Oncogene Protein Pipeline Drug Insight

*
Coverage: Global

*
Key Myc Proto Oncogene Protein Companies: Linnane Pharma, Peptomyc, Moleculin Biotech, Cothera Bioscience, EpicentRx, and others

*
Key Myc Proto Oncogene Protein Therapies: MYC degrader, OMO- 103, WP-1066, PC 002, RRx-001, and others

*
Myc Proto Oncogene Protein Therapeutic Assessment: Myc Proto Oncogene Protein current marketed and Myc Proto Oncogene Protein emerging therapies

*
Myc Proto Oncogene Protein Market Dynamics: Myc Proto Oncogene Protein market drivers and Myc Proto Oncogene Protein market barriers

Request for Sample PDF Report for Myc Proto Oncogene Protein Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/myc-proto-oncogene-protein-pipeline-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Myc Proto Oncogene Protein Report Introduction

2. Myc Proto Oncogene Protein Executive Summary

3. Myc Proto Oncogene Protein Overview

4. Myc Proto Oncogene Protein- Analytical Perspective In-depth Commercial Assessment

5. Myc Proto Oncogene Protein Pipeline Therapeutics

6. Myc Proto Oncogene Protein Late Stage Products (Phase II/III)

7. Myc Proto Oncogene Protein Mid Stage Products (Phase II)

8. Myc Proto Oncogene Protein Early Stage Products (Phase I)

9. Myc Proto Oncogene Protein Preclinical Stage Products

10. Myc Proto Oncogene Protein Therapeutics Assessment

11. Myc Proto Oncogene Protein Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Myc Proto Oncogene Protein Key Companies

14. Myc Proto Oncogene Protein Key Products

15. Myc Proto Oncogene Protein Unmet Needs

16 . Myc Proto Oncogene Protein Market Drivers and Barriers

17. Myc Proto Oncogene Protein Future Perspectives and Conclusion

18. Myc Proto Oncogene Protein Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myc-proto-oncogene-protein-clinical-trials-2024-fda-approvals-medication-therapies-moa-roa-and-companies-by-delveinsight-biogenera-spa-ceptur-therapeutics-inc-cothera-bioscience-more]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com



This release was published on openPR.